Peregrine reports positive cancer data
Peregrine Pharmaceuticals is posting positive data from two ongoing, mid-stage trials of its cancer therapy Cotara. The trial data assessed Cotara's safety and efficacy in treating patients with glioblastoma multiforme, a deadly form of brain cancer. The drug appeared to be safe and well tolerated, with no dose-limiting adverse events. And several volunteers surpassed the median expected survival time for relapsed GBM patients.
"In view of the short expected survival time of approximately six months in this patient population, it is promising that we have early GBM patients in these trials who have survived past the six-monthtimeframe, with one patient now surviving 15 months post-treatment," said Steven W. King, president and CEO of Peregrine.
- check out the release
Related Articles:
India OKs Peregrine trial. Report
Peregrine touts early avian flu virus data. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
